Showing 2231-2240 of 5696 results for "".
- OrCam Unveils Enhancements for MyEye and Read3 Devices at CEShttps://modernod.com/news/orcam-unveils-enhancements-for-myeye-and-read3-devices-at-ces/2482050/OrCam Technologies, which is focused on personal artificial intelligence (AI) assistive technology platforms, introduced new enhancements for its MyEye and Read3 devices at CES 2024, the Consumer Electronics Show held by the Consumer Technology Association on January 9-12 in Las Vegas, Nevada.
- Prevent Blindness Opens Nominations for the 2024 Jenny Pomeroy Award for Excellence in Vision and Public Health, and Rising Visionary Awardhttps://modernod.com/news/prevent-blindness-opens-nominations-for-the-2024-jenny-pomeroy-award-for-excellence-in-vision-and-public-health-and-rising-visionary-award/2482043/Prevent Blindness is issuing the call for nominations for the “2024 Jenny Pomeroy Award for Excellence in Vision and Public Health,” and the fifth annual “
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulationhttps://modernod.com/news/iridex-confirms-medicare-administrative-contractors-retired-local-coverage-determinations-that-restricted-cyclophotocoagulation/2482036/Iridex announced all five Medicare Administrative Contractors (MACs) retired their local coverage determinations (LCDs) that were scheduled to take effect on January 29, 2024. Iridex and other stakeholders opposing the LCDs have engaged with the MACs throughout the comment period to advocate
- LSU Health Discovery May Open New Therapeutic Avenues for Degenerative Diseases of the Brain and Eyehttps://modernod.com/news/lsu-health-discovery-may-open-new-therapeutic-avenues-for-degenerative-diseases-of-the-brain-and-eye/2482034/Scientists at LSU Health New Orleans’ Neuroscience Center of Excellence have identified a new mechanism that regulates a protein key for cell survival. It appears to protect against the excessive oxidative stress that precedes the development of neurodegenerative diseases of the brain and e
- Cellusion Receives FDA Orphan Drug Designation for CLS001https://modernod.com/news/cellusion-receives-fda-orphan-drug-designation-for-cls001/2482028/Cellusion announced that the FDA has granted orphan drug designation to its regenerative medicine product, “iPS cell-derived corneal endothelial cell substitute,” (CLS001) for the treatment of bullous keratopathy. FDA grants orphan drug designation if the drug
- Ocugen's OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of RP Associated with RHO Mutationshttps://modernod.com/news/ocugens-ocu400-receives-regenerative-medicine-advanced-therapy-rmat-designation-for-treatment-of-rp-associated-with-rho-mutations/2482019/Ocugen announced that the FDA has granted RMAT designation to Ocugen’s investigational product OCU400 for the treatment of retinitis pigmentosa (RP) associated with RHO mutations. “RMAT designation is a significant accomplishment for the OCU400 clinical develo
- Reichert to Distribute Imaging and Dry Eye Treatment Devices in the United Stateshttps://modernod.com/news/reichert-to-distribute-imaging-and-dry-eye-treatment-devices-in-the-united-states/2482016/Reichert Technologies, a business of AMETEK Inc., announced an exclusive partnership with SBM Sistemi of Italy to distribute SBM’s imaging and dry eye assessment and treatment devices in the United States. Financial terms of the deal were not disclosed. </
- NEI Study Shows How Genes in Retina Get Regulated During Developmenthttps://modernod.com/news/nei-study-shows-how-genes-in-retina-get-regulated-during-development/2482012/Using models of a retina grown in the lab, researchers at the National Eye Institute say they have mapped the 3D organization of genetic material of key developmental stages of human retinal formation. The findings lay a foundation for understanding clinical traits in many eye diseases, and
- Tarsus Announces Topline Phase 2a Trial Results Evaluating TP-03 for the Treatment of MGD in Patients with Demodex Miteshttps://modernod.com/news/tarsus-announces-topline-phase-2a-trial-results-evaluating-tp-03-for-the-treatment-of-mgd-in-patients-with-demodex-mites/2482004/Tarsus Pharmaceuticals announced topline results from the Ersa phase 2a clinical trial evaluating TP-03 (lotilaner ophthalmic solution, 0.25%) administered twice daily (BID) or three times a day (TID) for 12 weeks for the treatment of meibomian gland disease (MGD) in patients with Demodex&nb
- New "Eye Chart" App Designed to Address Common Challenges in Near Vision Testinghttps://modernod.com/news/new-eye-chart-app-designed-to-address-common-challenges-in-near-vision-testing/2481995/A new app aims to address common challenges encountered in near vision testing. The "Eye Chart" app, which was developed by Michael Ullman, MD, a cornea specialist at Ullman Eye Consultants in Pensacola, Florida, leverages the iPhone's TrueDepth camera to me